Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bacillus subtilis/Enterococcus faecium/mosapride

Next Previous
Search
Drug Profile

Bacillus subtilis/Enterococcus faecium/mosapride

Alternative Names: HCP 0613; Medilac/mosapride; Medirac/mosapride; Mosapride/Bacillus subtilis/Enterococcus faecium; Mosapride/Bacillus subtilis/Streptococcus faecium; Mosapride/Enterococcus faecium/Bacillus subtilis; Mosapride/Medilac; Mosapride/Medirac; Mosapride/probiotics; Probiotics/mosapride

Latest Information Update: 17 Aug 2015

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Bacteria; Benzamides; Gastrokinetics; Morpholines; Probiotics; Small molecules
  • Mechanism of Action Bacteria replacements; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 31 Jan 2012 Bacillus subtilis/Enterococcus faecium/mosapride is available for licensing
  • 01 May 2011 Phase-II clinical trials in Irritable bowel syndrome in South Korea (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top